Baseline demographics of all admission with AP by quintile
| Q1 | Q2 | Q3 | Q4 | Q5 | P value | |
| No | 156 | 94 | 60 | 48 | 38 | <0.001* |
| Age, mean (SD) | 52.4 (15.5) | 59.8 (15.) | 58.8 (14.4) | 59.5 (12.8) | 65.2 (13.7) | <0.001* |
| Gender (male %) | 97 (62%) | 58 (62%) | 42 (70%) | 27 (56%( | 19 (50%) | 0.341 |
| Medical history | ||||||
| Type 2 diabetes mellitus | 31 (19.9%) | 17 (18.1%) | 13 (21.7%) | 5 (10.4%) | 7 (18.4%) | 0.578 |
| Past alcohol dependence | 31 (19.9%) | 17 (18.1%) | 13 (21.7%) | 5 (10.4%) | 7 (18.4%) | 0.058 |
| Ischaemic heart disease | 148 (94.9%) | 76 (80.9%) | 55 (91.7%) | 47 (97.9%) | 35 (92.1%) | <0.001* |
| Hypertension | 47 (30.1%) | 30 (31.9%) | 20 (33.3%) | 14 (29.2%) | 16 (42.1%) | 0.627 |
| Chronic kidney disease | 8 (5.13%) | 9 (9.57%) | 2 (3.33%) | 2 (4.17%) | 1 (2.63%) | 0.375 |
| Chronic obstructive pulmonary disease | 14 (8.97%) | 8 (8.51%) | 2 (3.33%) | 1 (2.08%) | 1 (2.63%) | 0.228 |
| Cerebrovascular disease | 4 (2.56%) | 2 (2.13%) | 4 (6.67%) | 1 (2.08%) | 2 (5.26%) | 0.484 |
| Smoker | 61 (39.1%) | 23 (24.5%) | 12 (20%) | 12 (25%) | 9 (23.7%) | 0.044* |
| Alcohol aetiology | 99 (63.5%) | 54 (57.4%) | 28 (46.7%) | 31 (64.6%) | 19 (50%) | 0.119 |
| Gallstone aetiology | 51 (32.7%) | 36 (38.3%) | 22 (36.7%) | 22 (45.8%) | 18 (47.4%) | 0.334 |
| Premorbid ECOG | ||||||
| 1 | 35 (22.4%) | 29 (30.9%) | 16 (26.7%) | 15 (31.3%) | 13 (34.2%) | 0.75 |
| 2 | 14 (8.97%) | 9 (9.57%) | 6 (10%) | 2 (4.17%) | 2 (5.26%) | |
| 3 | 13 (8.33%) | 4 (4.26%) | 7 (11.7%) | 3 (6.25%) | 3 (7.89%) | |
| 4 | 3 (1.92%) | 1 (1.06%) | 0 (0%) | 0 (0%) | 1 (2.63%) | |
| Charlson Comorbidity Index | 2 (0–3) | 2 (1-4) | 2 (1-3) | 2 (1-3) | 3 (1.75–4) | 0.018 |
| Predicted 10-year survival | 90% (77%–98%) | 90% (53%–96%) | 90% (77%–98%) | 90% (77%–98%) | 77% (53%–91.5%) | 0.018 |
| Medical history of acute pancreatitis | 61 (39.1%) | 30 (31.9%) | 18 (30%) | 15 (31.3%) | 8 (21.1%) | 0.313 |
| Laboratory results | ||||||
| Amylase Median (IQR) | 451 (140–1419) | 702 (139–1872) | 939 (165–2054) | 864 (288–1891) | 1248 (86–1931) | 0.487 |
| C reactive protein Median (IQR) | 54 (6.5–190) | 32.1 (6.2–204) | 16.9 (5.0–158.3) | 14 (5.0–164.5) | 79.5 (8.0–185) | 0.914 |
| Albumin Mean (SD) | 37.0 (8.1) | 37.4 (7.2) | 38.8 (8.4) | 38.5 (7.1) | 37.6 (8.9) | 0.585 |
| Total protein Mean (SD) | 68.2 (10.6) | 69.1 (7.5) | 70.8 (7.2) | 69.1 (7.8) | 65.8 (8.2) | 0.152 |
| Alanine aminotransferase Median (IQR) | 38.5 (18-96) | 51 (20–163.5) | 72 (30–208) | 105.0 (29-265) | 106.0 (31.0–187) | 0.345 |
| Alkaline phosphatase Median (IQR) | 127(88-177) | 119.5 (84.5–171.5) | 120.0 (92.0–210) | 101 (84–150.5 | 122 (90–212) | 0.583 |
| Platelets | 290(210-387) | 286(232-376) | 262(218-338) | 268(223-304) | 302(198-386) | 0.660 |
| Prothrombin time | 15.2 (3.3) | 164 (6.7) | 16.0 (5.4) | 14.7 (3.2) | 15.2 (2.3) | 0.245 |
*Statistically significant at<0.05 level
ECOG, Eastern Cooperative Oncology Group